Chemotherapy for Advanced Transitional Cell Carcinoma of the Urothelium: Cisplatin or Carboplatin?

European Urology

Volumn 52, Issue 1, 2007, Pages 9-10

  Culine, Stéphane ^a  

^a CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIRUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; EDITORIAL; HUMAN; KIDNEY DISEASE; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; UROTHELIUM;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; HUMANS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 34248996895     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.01.017     Document Type: Editorial

References (8)

1. Sternberg C.N., Yagoda A., Scher H., et al. Preliminary results of MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 133 (1985) 403-407
2. Sternberg C.N., de Mulder P.H.M., Schornagel J.H., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924. J Clin Oncol 19 (2001) 2638-2646
3. von der Maase H., Dengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 (2005) 4602-4608
4. Petrioli R., frediani B., Manganelli A., et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. Cancer 77 (1996) 344-351
5. Bellmunt J., Ribas A., Eres N., et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80 (1997) 1966-1972
6. Dreicer R., Manola J., Roth B.J., et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100 (2004) 1639-1645
7. Dogliotti L., Cartenì G., Siena S., et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase II trial. Eur Urol 52 (2007) 134-141
8. Wieand H.S. Randomized phase II trials: what does randomization gain?. J Clin Oncol 23 (2005) 1794-1795